The alliance between the two companies focused on development of molecules for a range of therapeutic areas, economictimes.indiatimes.com reported.
Jubilant Life Sciences’ wholly-owned subsidiary Jubilant Biosys has entered a 50:50 JV with Eli Lilly in late 2008.
The partnership laid emphasis on developing molecules from the pre-clinical to phase II stage spanning many areas including oncology, diabetes and cardiovascular segments.